Cart
sales@molnova.com
Manassantin B
CAS No. 88497-88-5
Manassantin B( —— )
Catalog No. M32136 CAS No. 88497-88-5
Manassantin B is a potent inhibitor of NF-?oB activation by the suppression of transciptional activity of RelA/p65 subunit of NF-?oB.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 243 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
Biological Information
-
Product NameManassantin B
-
NoteResearch use only, not for human use.
-
Brief DescriptionManassantin B is a potent inhibitor of NF-?oB activation by the suppression of transciptional activity of RelA/p65 subunit of NF-?oB.
-
DescriptionManassantin B is a potent inhibitor of NF-?oB activation by the suppression of transciptional activity of RelA/p65 subunit of NF-?oB. It also possesses anti-EBV lytic replication activity. Manassantin B inhibits interleukin-6-induced signal transducer and activator of transcription 3 activation in Hep3B cells, it has potential as a potent anti-inflammatory drug for use in pathological processes such as sepsis or acute lung injury. Manassantin B exerts antifibrotic activity in HSC-T6 cells, in part, via inhibition of cell proliferation and decrease of collagen production.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number88497-88-5
-
Formula Weight716.8
-
Molecular FormulaC41H48O11
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Mebeverine hydrochlo...
Mebeverine is a drug whose major therapeutic role is in the treatment of irritable bowel syndrome (IBS) and the associated abdominal cramping.
-
Indole-3-methanamine
Indole-3-methanamine has been detected, but not quantified in, barley, cereals, and cereal products.
-
Bosutinib hydrate
Bosutinib (hydrate) is an oral Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively.
